MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to US$400 million in the company, including up to US$375 million in non-dilutive capital for capped royalty payments on certain products and up to US$25 million in equity.
Latham & Watkins LLP represents MeiraGTx in the transaction with a finance team led by partner Todd Trattner, with associates Jing Cao and Will Sedgwick. Advice was also provided on corporate matters by partners Keith Halverstam and Jennifer Yoon; on healthcare regulatory matters by partners Betty Pang and Nathan Beaton, with associate Evan Miller; on tax matters by partners Eric Cho and Karl Mah, with associate Sam Duncan; on ERISA matters by partner Julie Crisp; on intellectual property matters by partner John McGaraghan, with associate Preeta Reddy; on data privacy and cybersecurity matters by partner Heather Deixler; on UK finance matters by Ross Pooley, with associates Emma Lynam, Dominic Puri, and Ohana Mei Naidu; on UK real estate matters by partners Quentin Gwyer and Calvin Ng, with associates Sam Emmett and Costa Thrasyvoulou; on US finance matters by partner Dennis Lamont; and on funds regulatory matters by Washington, D.C. counsel Meghan Carey, with associate Katherine Ryan.
